Opioid treatment programs, telemedicine and COVID-19: A scoping review

References

• Substance Abuse and Mental Health Services Administration. Statutes, regulations, and guidelines. https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines. Accessed August 31, 2020.
   Google Scholar
• Joudrey PJ, Edelman EJ, Wang EA. Drive times to opioid treatment programs in urban and rural counties in 5 US States. JAMA. 2019;322(13):1310–1312.
   PubMed Web of Science ®Google Scholar
• Madras BK. The President's Commission on combating drug addiction and the opioid crisis: origins and recommendations. Clin Pharmacol Ther. 2018;103(6):943–945.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration (DEA), Department of Justice. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. DEA and Department of Justice. Federal Register. 2009;74(64):15595–15625. https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr0930_2.htm
   Google Scholar
• Substance Abuse and Mental Health Services Administration. FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed August 31 2020.
   Google Scholar
• Grebely J, Cerda M, Rhodes T. COVID-19 and the health of people who use drugs: what is and what could be? Int J Drug Policy. 2020;83:102958.
   PubMed Web of Science ®Google Scholar
• Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.
   PubMed Web of Science ®Google Scholar
• Sucharew H, Macaluso M. Progress notes: methods for research evidence synthesis: the scoping review approach. J Hosp Med. 2019;14(7):416–418.
   PubMed Web of Science ®Google Scholar
• King VL, Stoller KB, Kidorf M, et al. Assessing the effectiveness of an Internet-based videoconferencing platform for delivering intensified substance abuse counseling. J Subst Abuse Treat. 2009;36(3):331–338.
   PubMed Web of Science ®Google Scholar
• King VL, Brooner RK, Peirce JM, Kolodner K, Kidorf MS. A randomized trial of web-based videoconferencing for substance abuse counseling. J Subst Abuse Treat. 2014;46(1):36–42.
   PubMed Web of Science ®Google Scholar
• Eibl JK, Gauthier G, Pellegrini D, et al. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017;176:133–138.
   PubMed Web of Science ®Google Scholar
• Guille C, Simpson AN, Douglas E, et al. Treatment of opioid use disorder in pregnant women via telemedicine: a nonrandomized controlled trial. JAMA Netw Open. 2020;3(1):e1920177.
   PubMed Web of Science ®Google Scholar
• Zheng W, Nickasch M, Lander L, et al. Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis. J Addict Med. 2017;11(2):138–144.
   PubMed Web of Science ®Google Scholar
• Weintraub E, Greenblatt AD, Chang J, et al. Outcomes for patients receiving telemedicine-delivered medication-based treatment for opioid use disorder: a retrospective chart review. Heroin Addict Relat Clin Probl. 2021;23(2):5–12.
   PubMed Web of Science ®Google Scholar
• Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612–617.
   PubMed Web of Science ®Google Scholar
• Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus. 2020;1–8.
   PubMed Web of Science ®Google Scholar
• Tofighi B, McNeely J, Walzer D, et al. A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC Public Hospital System's initiative to expand treatment access during the COVID-19 pandemic. J Addict Med. 2021.
   PubMedGoogle Scholar
• McCarty D, Chan B, Hoffman K, et al. Methadone Treatment Regulations in the United States: History, Current Status, Evidence, and Policy Considerations Portland, or, Northwest Evidence-Based Practice Center. Oregon Health & Science University; 2020.
   Google Scholar
• Nunes EV, Levin FR, Reilly MP, El-Bassel N. Medication treatment for opioid use disorder in the age of COVID-19: can new regulations modify the opioid cascade? J Subst Abuse Treat. 2021;122:108196.
   PubMed Web of Science ®Google Scholar
• Uscher-Pines L, Huskamp HA, Mehrotra A. Treating patients with opioid use disorder in their homes: an emerging treatment model. JAMA. 2020;324(1):39–40.
   PubMed Web of Science ®Google Scholar
• Kleinman RA. Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry. 2020;77(11):1163–1171.
   PubMed Web of Science ®Google Scholar
• Hser YI, Mooney LJ. Integrating telemedicine for medication treatment for opioid use disorder in rural primary care: beyond the COVID pandemic. J Rural Health. 2021;37(1):246–248.
   PubMed Web of Science ®Google Scholar
• Hansen H, Roberts SK. Two Tiers of Biomedicalization: Methadone, Buprenorphine, and the Racial Politics of Addiction Treatment. Critical Perspectives on Addiction. Bingley: Emerald Group Publishing Limited; 2012.
   Google Scholar
• Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367–377.
   PubMed Web of Science ®Google Scholar
• Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. J Subst Abuse Treat. 2021;122:108214.
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–981.
   PubMed Web of Science ®Google Scholar
• Khoong EC, Butler BA, Mesina O, et al. Patient interest in and barriers to telemedicine video visits in a multilingual urban safety-net system. J Am Med Inform Assoc. 2021;28(2):349–353.
   PubMed Web of Science ®Google Scholar
• Schifeling CH, Shanbhag P, Johnson A, et al. Disparities in video and telephone visits among older adults during the COVID-19 pandemic: cross-sectional analysis. JMIR Aging. 2020;3(2):e23176.
   PubMedGoogle Scholar
• Yang J, Landrum MB, Zhou L, Busch AB. Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts. Gen Hosp Psychiatry. 2020;67:100–106.
   PubMed Web of Science ®Google Scholar
• Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abuse Treat. 2019;101:38–49.
   PubMed Web of Science ®Google Scholar
• Cantor J, Stein BD, Saloner B. Telehealth capability among substance use disorder treatment facilities in counties with high versus low COVID-19 social distancing. J Addict Med. 2020;14(6):e366–e368.
   PubMed Web of Science ®Google Scholar
• Castillo M, Conte B, Hinkes S, et al. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):88.
   PubMed Web of Science ®Google Scholar
• Hughto JMW, Peterson L, Perry NS, et al. The provision of counseling to patients receiving medications for opioid use disorder: telehealth innovations and challenges in the age of COVID-19. J Subst Abuse Treat. 2021;120:108163.
   PubMed Web of Science ®Google Scholar
• Komaromy M, Tomanovich M, Taylor JL, et al. Adaptation of a system of treatment for substance use disorders during the COVID-19 pandemic. J Addict Med. 2020;
   PubMed Web of Science ®Google Scholar
• Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat. 2020;118:108124.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. https://emergency.cdc.gov/han/2020/han00438.asp. Accessed January 19 2021.
   Google Scholar